Research programme: Parkinson's disease therapies - Proteome Systems
Alternative Names: EUK-418Latest Information Update: 16 Jan 2009
Price :
$50 *
At a glance
- Originator Proteome Systems
- Developer Tyrian Diagnostics
- Class Small molecules
- Mechanism of Action Free radical scavengers; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 10 May 2007 Preclinical trials in Parkinson's disease in USA (PO)